BioQ Pharma and Cipla the signed of a strategic distribution, supply and development agreement for the registration and commercialization of BioQ Pharma's Ropivacaine infusion pharmaceutical in India.
BioQ Pharma's unit dose infusion pharmaceuticals have been developed as readyto use presentations in which the drugs and administration systems are self-contained and delivered at the point of care. In particular, the Ropivacaine infusion system is pre filled, ready to use at the point of care, and intended to provide a safer, more efficient continuous infusion postoperative pain solution.
Josh Kriesel, Pres ident and CEO of BioQ Pharma, remarked, "We are excited to collaborate with Cipla as we expand our worldwide commercial footprint into India. We believe India is an excellent market to help expand our objective of establishing a new standard of care in the presentation and administration of infusible pharmaceuticals. Cipla's proven, hospital focused sales and marketing organization will be essential in introducing BioQ Pharma's proprietary unit dose, large volume infusion pharmaceuticals to India’s healthca re market, which we believe will benefit from our product’s value add proposition of increased safety, sterility and convenience.
"Nikhil Chopra, Head of Cipla’s India Business, added, "We are very pleased to partner with BioQ Pharma in introducing the Ropivacaine unit dose infusion system to patients and caregivers in India. We believe that this innovative product represents a significant evolution in enhancing the delivery of infusions and managing post-surgical pain.
